RegeneRx Biopharmaceuticals Inc (RGRX) Given a $2.00 Price Target by HC Wainwright Analysts
HC Wainwright set a $2.00 price objective on RegeneRx Biopharmaceuticals Inc (NASDAQ:RGRX) in a research report sent to investors on Tuesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Shares of RegeneRx Biopharmaceuticals (NASDAQ RGRX) opened at 0.28 on Tuesday. The company’s 50 day moving average is $0.27 and its 200 day moving average is $0.28. RegeneRx Biopharmaceuticals has a one year low of $0.22 and a one year high of $0.40. The company has a market cap of $29.93 million and a P/E ratio of 25.45.
About RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide.
Receive News & Stock Ratings for RegeneRx Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals Inc and related stocks with our FREE daily email newsletter.